Aveva Drug Delivery Systems Prevails on Appeal, Federal Circuit Affirms Non-Infringement of ZTlido® Patents - Prepares for an Imminent Launch of its Generic Product with 180 Day Exclusivity
MIRAMAR, Fla., Aug. 5, 2026 /PRNewswire/ -- Aveva Drug Delivery Systems, Inc. ("Aveva"), a company in the DifGen Pharmaceuticals family, today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a District Court's opinion of non-infringement in the matter...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.